Xiaofeng Wu

METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer

Weijun Wan, Xiang Ao, Quan Chen et al. · Molecular Cancer · 2022 · 478 citations · Full text

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial

Yongxiang Xia, Weiwei Tang, Xiaofeng Qian et al. · Journal for ImmunoTherapy of Cancer · 2022 · 192 citations · Full text

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial

Xiaofeng Chen, Xiaofeng Wu, Hao Wu et al. · Journal for ImmunoTherapy of Cancer · 2020 · 156 citations · Full text

Immunology, Pathology, Metronomic Chemotherapy +17

Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer

Elizabeth A. McMillan, Myung-Jeom Ryu, Caroline H. Diep et al. · Cell · 2018 · 145 citations · Full text

Oncology, Medicine, Bronchial Neoplasm +4

HDAC2 inhibits EMT-mediated cancer metastasis by downregulating the long noncoding RNA H19 in colorectal cancer

Xueting Hu, Wei Xing, Rong-sen Zhao et al. · Journal of Experimental & Clinical Cancer Research · 2020 · 140 citations · Full text